Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

118

54. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to
    defi ning functional ability in ankylosing spondylitis: the development of the bath ankylosing
    spondylitis functional index. J Rheumatol. 1994;21(12):2281–5.


55. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing spondylitis
    disease activity score (ASDAS): defi ning cut-off values for disease activity states and
    improvement scores. Ann Rheum Dis. 2011;70(1):47–53.


56. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham vascu-
    litis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med. 1994;87(11):671–8.


57. Whiting O’Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for
    systemic necrotizing vasculitis. Arthritis Rheum. 1999;42:2365–71.


58. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-
    specifi c activity index for Wegener’s granulomatosis: modifi cation of the Birmingham vascu-
    litis activity score. Arthritis Rheum. 2001;44(4):912–20.


59. Pincus T, Yazici Y, Sokka T. Quantitative measures of rheumatic diseases for clinical research
    versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin
    Rheumatol. 2007;21(4):601–28.


60. Wolfe F, Michaud K. The clinical and research signifi cance of the erythrocyte sedimentation
    rate. J Rheumatol. 1994;21:1227–37.


61. Bowling A. Measuring disease: a review of disease-specifi c quality of life measurement
    scales, vol. 2. Buckingham: Open University Press; 2001. p. 25–6.


62. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.


63. Ebrahim S, Barer D, Nouri F. Use of the Nottingham Health Profi le with patients after a
    stroke. J Epidemiol Community Health. 1986;40(2):166–9.


64. Meadows K. Patient-reported outcome measures: an overview. Br J Community Nurs.
    2011;16(3):146–51.


65. Pincus T, Yazici Y, Bergman M. Development of a multi-dimensional health assessment
    questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol.
    2005;23 Suppl 39:S19–28.


66. Nicklin J, Cramp F, Kirwan J, Greenwood R, Urban M, Hewlett S. Measuring fatigue in
    rheumatoid arthritis: a cross-sectional study to evaluate the Bristol rheumatoid arthritis
    fatigue multi-dimensional questionnaire, visual analog scales, and numerical rating scales.
    Arthritis Care Res. 2010;32:1559–68.


67. Osterhaus JT. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-
    specifi c work productivity survey (WPS-RA). Arthritis Res Ther. 2009;11:R73.


68. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional health assessment question-
    naire (MDHAQ): assessment of advanced activities of daily living and psychological status
    in the patient-friendly health assessment questionnaire format. Arthritis Rheum.
    1999;42:2220–30.


69. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, et al.
    Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-
    derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann
    Rheum Dis. 2011;70(6):935–42.


70. Pincus T. Pain, function, and RAPID scores: vital signs in chronic diseases, analogous to
    pulse and temperature in acute diseases and blood pressure and cholesterol in long-term
    health. Bull NYU Hosp Joint Dis. 2008;66(2):155–65.


71. El Miedany Y, Palmer D, El Gaafary M. Further analysis of helplessness measurement in
    infl ammatory arthritis/spondyloarthritis: the development of the modifi ed rheumatology atti-
    tude index. Rheumatology (Oxford). 2010;49(S1):162.


72. Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Ostergaard M, et al.
    Proposal for levels of evidence schema for validation of a soluble biomarker refl ecting
    damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and
    recommendations for study design. J Rheumatol. 2009;36(8):1792–9.


73. Biomarkers Defi nition Working Group. Biomarkers and surrogate endpoints: preferred defi -
    nitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.

Y. El Miedany